Abstract: Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients, are provided. Certain of the systems and methods described herein are capable of manufacturing multiple chemical products without the need to fluidically connect or disconnect unit operations when switching from one making chemical product to making another chemical product.

Abstract: A method of depolymerizing a polyester in a waste material is disclosed. The method comprises: supplying the waste material comprising the polyester to a depolymerization vessel; depolymerizing the polyester to form a depolymerized mixture comprising a regenerated diol, a regenerated diacid, and a catalyst; isolating the regenerated diacid and the catalyst from the regenerated diol to form a regenerated composition including the regenerated acid and the catalyst; and separating the regenerated composition from the regenerated diol. In addition, a regenerated composition formed from depolymerization of a waste material is disclosed wherein the regenerated composition comprises a regenerated diacid and a catalyst and wherein the catalyst is present in an amount of from 5 ppm to 300 ppm.

Abstract: A method of obtaining a purified regenerated diacid from a depolymerization of a polyester in a waste material wherein the depolymerization provides a depolymerized mixture comprising a regenerated diol, a regenerated diacid, and a catalyst is disclosed. The method comprises: separating a regenerated composition including the regenerated acid and the catalyst from the regenerated diol; providing the regenerated composition in a liquid medium to form a pre-aged mixture; subjecting the pre-aged mixture to thermal cycling wherein the cycling occurs within 25° C. and within a temperature range of from 150° C. or more to 300° C. or less to form an aged mixture; and separating the regenerated composition from the liquid medium in the aged mixture.

Abstract: A method of forming a polyester from a regenerated composition comprising a regenerated diacid and a catalyst obtained from depolymerization of a polyester in a waste material is disclosed. The method comprises: reacting a diol and the regenerated diacid in the regenerated composition to form one or more compounds including an ester bond; optionally providing additional catalyst; and polymerizing the one or more compounds including an ester bond to form a polyester.

Abstract: Materials containing pharmaceutically active species in solid (e.g., crystal) form, and related methods, are provided, allowing for improved stability, solubility, bioavailability, and/or dissolution rates for pharmaceutically active species having poor aqueous solubility.

Abstract: The present invention generally relates to methods and systems relating to the selection of substrates comprising crystalline templates for the controlled crystallization of molecular species. In some embodiments, the methods and systems allow for the controlled crystallization of a molecular species in a selected polymorphic form. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent).

Abstract: The present disclosure is generally related to the separation of liquids from solids and for the recovery of solids and/or liquids from slurries. In some embodiments, liquids are separated from solids by applying a reduced pressure. In some embodiments, slurries are flowed by applying a pressure gradient. In some embodiments, an apparatus is provided that comprises a channel, an inlet, an outlet, and one or more ports. One or more ports may be constructed and arranged to apply a pressure differential and/or a reduced pressure to the channel. Such systems and methods may, in some embodiments, facilitate continuous manufacturing of solid products.

Abstract: The present invention generally relates to devices and methods for crystallizing a compound. In certain industries, crystallization techniques require additional filtration steps in order to obtain products of relatively high yield and/or high purity. In some embodiments, the devices and methods described herein facilitate continuous production of high yield and/or high purity products without the need for additional filtration steps. In some embodiments, the devices and methods comprise flowing a fluid comprising a compound (e.g., a crystallizable compound, a solidifiable compound) over a substrate such that the compound crystallizes and/or precipitates on the substrate. In some embodiments, the crystallized compound can be recovered (e.g., at a high purity in solution). In certain embodiments, the substrate is orientated substantially vertically (e.g., such that flow of the fluid is driven by gravity). In some cases, the substrate comprises a plurality of crystallization promoting structures.

Abstract: Methods of heterogeneous crystallization and related systems are provided. In some embodiments, a method comprises crystallizing an agent in a suspension comprising a heteronucleant and the dissolved agent. Crystallization may occur on the surface of the heteronucleant with little or no bulk crystallization and/or secondary nucleation. In some embodiments, a crystallizer may be configured to inhibit secondary nucleation and/or bulk crystallization, for example, by reducing the formation of free crystals that may serve as nucleation surfaces while allowing for adequate mass and heat transfer. In some such embodiments, the crystallizer may be designed to flow (e.g., continuously) a suspension comprising a heteronucleant and an agent in a fluidized state. The methods and systems of the present invention may be used in a wide variety of applications, including the crystallization of pharmaceutically active agents.

Abstract: The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent).

Abstract: The present invention provides methods to treat mixtures containing natural rebaudioside A (Reb A), rebaudioside B (Reb B), and rebaudioside D (Reb D), synthetic counterparts of these, and/or derivatives of the natural or synthetic embodiments obtain one or more of these glycosides in more pure form. In many embodiments, the invention can be used to process glycoside mixtures obtained at least in part from natural sources such as the Stevia plant. This allows, for instance, the recovery of a product including Reb A material in more pure form relative to Reb B material or Reb D material. As an alternative or in addition to recovery of the purified Reb A material, a product including Reb B material and/or Reb D material in more pure form relative to Reb A material can be obtained.

Abstract: The invention in some aspects relates to devices and methods for nucleating crystals under controlled conditions. In some aspects of the invention, devices and methods are provided for continuous crystallization.

Abstract: Layer processing for pharmaceuticals, and related systems, methods, and articles are generally described. In some embodiments, ingestible pharmaceutical products (e.g., tablets) can be formed by processing one or more layers containing a pharmaceutically active composition. For example, at least one layer containing a pharmaceutically active composition can be manipulated (e.g., folded, rolled, stacked, etc.) such that the average thickness of the product formed by the manipulation is at least about two times the average thickness of the portions of the layer(s) used to form the product. In some embodiments, after the layer is manipulated, it can be processed (e.g., cut, coated, etc.) to form a final product such as, for example, a tablet.

Abstract: The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent).

Abstract: Compositions, methods, and systems for controlling crystallization of an agent are generally described. In some embodiments, an agent is crystallized in the presence of polymer matrices, such as polymer particles. The polymer matrix may influence at least a portion of the crystallization process and/or the resulting composition. In some such embodiments, the polymer matrix allows one or more aspect of the process and/or composition to be controlled and/or altered. For instance, the polymer matrix may act as a crystallization promoter and/or acceptable carriers of the crystallized agent. In certain embodiments, the polymer matrix described herein, can be used with any agent regardless of its chemical and/or physical properties.

Abstract: The invention in some aspects relates to devices and methods for nucleating crystals under controlled conditions. In some aspects of the invention, devices and methods are provided for continuous crystallization.

Abstract: Electrospinning of crystalline particles comprising active pharmaceutical ingredients (API) from suspensions yields fibrous compositions comprising the API. The morphology and size of the crystalline particles may be preserved. The particles may be predominantly retained by fibers and distributed throughout the fibrous mesh. Tablet forms of the APIs prepared from the fibrous compositions demonstrate higher dissolution rates than tablets prepared from compacted powders of the APIs.

Abstract: Layer processing for pharmaceuticals, and related systems, methods, and articles are generally described. In some embodiments, ingestible pharmaceutical products (e.g., tablets) can be formed by processing one or more layers containing a pharmaceutically active composition. For example, at least one layer containing a pharmaceutically active composition can be manipulated (e.g., folded, rolled, stacked, etc.) such that the average thickness of the product formed by the manipulation is at least about two times the average thickness of the portions of the layer(s) used to form the product. In some embodiments, after the layer is manipulated, it can be processed (e.g., cut, coated, etc.) to form a final product such as, for example, a tablet.

Abstract: The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent).